Oncologists should see 2005 Medicare pay exceed drug costs for many of the top-billed cancer drugs, GAO finds

Article Overview

This article summarizes a GAO report on Medicare payment levels for physician-administered cancer drugs and compares estimated reimbursement with acquisition cost for a set of commonly billed oncology drugs. It is relevant to oncology practices, medical billing and coding staff, reimbursement analysts, and anyone tracking Medicare drug payment methodology and its financial impact on office-based cancer care. The article includes a table of drug payment comparisons and references the underlying GAO report and Medicare payment context.